The health and economic burden of rotavirus disease in Belgium
- 4 March 2008
- journal article
- research article
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 167 (12) , 1409-1419
- https://doi.org/10.1007/s00431-008-0684-3
Abstract
For health economic evaluations of rotavirus vaccination, estimates of the health and cost burden of rotavirus are required. Due to differences in health care systems and surveillance organisations, this is difficult to achieve by imputing estimates from one country to others. This study aimed to estimate the burden of rotavirus disease in Belgium. In children younger than 7 years of age, rotavirus is predicted to account annually for about 5,600 hospitalisations (676:100,000 children); 26,800 outpatient, general practitioner and paediatrician visits; and about 44,600 episodes for which no medical care is sought. This burden is estimated to represent direct costs of 7.7 million € and indirect costs of 12.8 million €. Rotavirus disease causes a substantial health and economic burden in Belgium.Keywords
This publication has 38 references indexed in Scilit:
- Costs of Community‐Acquired Pediatric Rotavirus Gastroenteritis in 7 European Countries: The REVEAL StudyThe Journal of Infectious Diseases, 2007
- Multicenter Prospective Study of the Burden of Rotavirus Acute Gastroenteritis in Europe, 2004–2005: The REVEAL StudyThe Journal of Infectious Diseases, 2007
- Infantile gastroenteritis in the community:a cost-of-illness studyEpidemiology and Infection, 2007
- Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United KingdomEpidemiology and Infection, 2007
- Rotavirus gastroenteritis: epidemiological data from a regional hospital in BelgiumEuropean Journal of Pediatrics, 2007
- Efficacy, Immunogenicity, and Safety of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine at the End of Shelf LifePediatrics, 2007
- Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infantsVaccine, 2006
- Nosocomial Rotavirus Infection in European CountriesThe Pediatric Infectious Disease Journal, 2006
- Evaluation of RIX4414, A Live, Attenuated Rotavirus Vaccine, in a Randomized, Double‐Blind, Placebo‐Controlled Phase 2 Trial Involving 2464 Singaporean InfantsThe Journal of Infectious Diseases, 2005
- The difficult quest for data on “vanishing” vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium)Vaccine, 2002